GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (FRA:4DN) » Definitions » Total Debt per Share

Denali Therapeutics (FRA:4DN) Total Debt per Share : €0.33 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Denali Therapeutics Total Debt per Share?

€0.33 (As of Mar. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Denali Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2024 was €0.33.

Denali Therapeutics Total Debt per Share Historical Data

The historical data trend for Denali Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Total Debt per Share Chart

Denali Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only 0.68 0.47 0.46 0.42 0.35

Denali Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.37 0.37 0.35 0.33

Denali Therapeutics Total Debt per Share Calculation

Denali Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(41.2+6.7)/138.4
=0.35

Denali Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(39.6+6.9)/142.5
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics (FRA:4DN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (FRA:4DN) » Definitions » Total Debt per Share
Comparable Companies
ARWR MDGL MLTX FTRE RARE DNA CORT AXSM BHVN TRML OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
DNLI:USA 4DN:Germany
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Website
https://www.denalitherapeutics.com
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Denali Therapeutics (FRA:4DN) Headlines

No Headlines